上客户端，和病友交流
点击下载
返回
乳腺癌
Lawrence Flaherty M.D.

Lawrence Flaherty M.D.

外科
Karmanos cancer center

擅长疾病

临床新药咨询

通过咨询找到适合自己的药物

专家会诊咨询

专业、及时的一对一咨询

如果您的问题未能解决，您还可以选择：

医学顾问

极速问诊

2万名名医
7*24小时为您匹配
1对1

找专家

肿瘤专科专家
对症找医专科专治

专家介绍

2015-06-18 14:272276
 ·         Gender

·         Male

·         Multidisciplinary Team(s)

·         Breast Cancer 
Melanoma/Skin 

·         Department/Research Program(s)

·         Department of Oncology 

·         Cancer Type(s)

·         Breast cancer 
Melanoma 

·         Contact Info

·         Email:
flaherty@karmanos.org

·         Education

·         Fellowship
Medical oncology - Mt. Sinai Hospital, Milwaukee, WI
Fellowship
Medical oncology - Hospital of the University of Pennsylvania, Philadelphia, PA
Medical School
St. Louis University School of Medicine
Residency
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Chief Medical Resident - Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI
Residency
Internal Medicine, Hematology/Oncology

·         Professional Memberships/Associations

·         American Society of Clinical Oncology 
Southwest oncology Group 
American College of Physicians 
Board of Directors, Michigan Society of Hematology and Oncology 

·         Board Certifications

·         American Board of Internal Medicine
American Board of Oncology
American Board of Hematology

·         Clinical Interests

·         Medical Oncologist 

·         Research Interests

·         Multidisciplinary care of patients with breast cancer and melanoma. Clinical research trials. 

·         Profile

·         Lawrence Flaherty's research interests, funded by the National Cancer Institute and several pharmaceutical studies, focus on the treatment of malignant melanomas, breast cancer and other solid tumors with a variety of experimental and traditional cancer therapeutics including Interleukin-2. Flaherty is on the board of the Southwest oncology Group (SWOG) and a member of the ASCO Education Committee and a member of the NCI-H Cooperative group study section. Flaherty has received numerous awards including the Barbara Ann Karmanos Cancer Institute's President's Achievement Award in Clinical Service for 2000 and being listed for several years in the Best Doctors in America. He has authored more than 70 articles in peer-reviewed journals and written four book chapters, and has reviewed for numerous journals. Flaherty received his B.S. (1974) from the University of Notre Dame and his M.D. (1978) from the St. Louis University School of Medicine (St. Louis, Missouri). He completed an internship (1979) and residency (1981) and was the Chief Medical Resident (1982) at the Medical College of Wisconsin Affiliated Hospitals in Milwaukee, Wisconsin. He completed fellowships in Hematology-oncology at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania (1986).

·         Awards

·         Best Doctors in America
Top Physicians in Detroit
2000 Karmanos Cancer Center, Clinical Excellence Award
2000 Karmanos Cancer Center – President’s Achievement Award in Clinical Service
Voted one of Best Doctors Inc. 2011-2012 Best Doctors of the Year

·         Publications

·         Phase III Trial Comparing Concurrent Biochemotherapy with Cisplatin, Vinblastine, Darcarbazine, Interleuken-2, and Interferon Alfa-2b with Cisplatin, Vinblastine, and Darcarbazine Alone in Patients with metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative oncology Group. J Clin oncol 26:5748-5754, 2008. PMID: 19001327. Authors: Atkins, M.B., Hsu, J., Lee S., Cohen G.I., Flaherty, L.E., Sosman, J.A., Sondak V.K., Kirwood J.M.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Kin): A Southwest oncology Group Study (S0331). Am J Clin oncol 2009 Dec 16 [Epub ahead of print]. PMID: 20019577. Authors: Samlowski W.E., Moon J., Tuthill R.J., Heinrich M.C., Balzer-Haas N.S., Merl S.A., Deconti R.C., Thompson J.A., Witter M.T., Flaherty L.E., Sondak V.K..
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest oncology Group S0508. Cancer 116(2)424-31, 2010. PMID: 19918923. Authors: Clark J.I., Moon J., Hutchins L.F., Sosman J.A., Kast W.M, Da Silva D.M., Liu P.Y., Thompson J.A., Flaherty L.E., Sondak V.K.
A Study of Paclitaxel, Carboplatin, and Bortezomib in The Treatment of metastatic Malignant Melanoma: A Phase 2 Consortium Study. Cancer 2010 Jul 15; 116(14):3463-8. PMID: 20564112. Authors: Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, Eckardt J, Ma C, Markovic SN, Erlichman C.
A Phase II Trial of Imatinib Mesylate in Merkel Cell Carcinoma (Neuroendocrine Carcinoma of the Skin). Am J Clin oncol 33(5):495-499, 2010. PMID 20019577. Authors: Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Palzer-Haas NS, Merl SA, DeConti RC, Thompson JA, Witter MT, Flaherty LE, Sondak VK.

  

1. 添加医学顾问微信，扫描☟二维码

2. 备注【癌种】进病友群

扫描预约专家问诊

专家科普

同类全球会诊
合作伙伴：